How to Internal medicine?

Gastric retention controlled drug delivery system,Deciding on patient electric shock therapy,Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer,Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators,Pta089 protein

Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

8 results about "Internal medicine" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Internal medicine or general medicine (in Commonwealth nations) is the medical specialty dealing with the prevention, diagnosis, and treatment of adult diseases. Physicians specializing in internal medicine are called internists, or physicians (without a modifier) in Commonwealth nations. Internists are skilled in the management of patients who have undifferentiated or multi-system disease processes. Internists care for hospitalized and ambulatory patients and may play a major role in teaching and research.

Gastric retention controlled drug delivery system

ActiveUS20040180088A1Maintain physical integrityFast swellingOrganic active ingredientsNervous disorderControlled drugsControl release

The present invention provides a gastric retention controlled drug delivery system comprising: (a) a controlled release core comprising a drug, a highly swellable polymer and a gas generating agent, said core being capable of swelling and achieving floatation rapidly while maintaining its physical integrity in gastrointestinal fluids for prolonged periods, and (b) a rapidly releasing coat composition comprising the same drug as in the core and pharmaceutically acceptable excipients, wherein the coating composition surrounds the core such that the system provides a biphasic release of the drug in gastrointestinal fluids.

Owner:SUN PHARMA INDS

Deciding on patient electric shock therapy

ActiveUS20110082510A1Improve patient outcomesHeart defibrillatorsElectric shock therapyElectric shock

Systems, devices, software and methods are provided, for making a decision as to whether to administer an electric shock to a patient. The decision can be made differently, depending on whether the patient has already been shocked or not.

Owner:PHYSIO CONTROL INC

Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer

InactiveUS20160024591A1Health-index calculationMicrobiological testing/measurementGenetic markerProstate cancer risk

The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various genetic markers associated with an increased risk of having or developing aggressive prostate cancer.

Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer

View all

Owner:WAKE FOREST UNIVERSITY +1

Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators

ActiveUS20170233808A1Reduces CD8+ T cell exhaustionReduce exhaustMicrobiological testing/measurementDisease diagnosisT cellInternal medicine

The present invention is based on the identification, of compositions and methods for the identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators.

Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators

View all

Owner:DANA FARBER CANCER INST INC +1

Pta089 protein

InactiveUS20120058131A1Avoid developmentSymptoms improvedMicrobiological testing/measurementDepsipeptidesProstate cancerOncology

The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development.

Owner:OXFORD BIOTHERAPEUTICS

Methods related to the diagnosis of prostate cancer

PendingUS20210333280A1Lower the volumeHealth-index calculationVaccination/ovulation diagnosticsAntigenPsa antigen

Disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising measuring the level of one or more polyamines in a fluid sample obtained from the subject, measuring at a variable selected from the group consisting of age, prostate volume (PV), prostate-specific antigen (PSA), digital rectal examination (DRE), and combinations thereof. Also disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising obtaining a score value based on previously disclosed variables to predict the likelihood of the subject developing or having prostate cancer.

Methods related to the diagnosis of prostate cancer

View all

Owner:YATHING BIOTECHNOLOGY CO LTD

Predictive and Prognostic Methods in Breast Cancer

PendingUS20210363594A1Increase probabilityOrganic active ingredientsMicrobiological testing/measurementComplete remissionIV Chemotherapy

The present invention relates to methods of predicting the probability of pathological complete response (pCR) of a breast cancer patient upon neo-adjuvant chemotherapy, to methods for selecting a breast cancer treatment, to methods of treatment of breast cancer, and to methods of prognosis of breast cancer upon breast cancer treatment.

Predictive and Prognostic Methods in Breast Cancer

View all

Owner:BIONTECH DIAGNOSTICS +1

Methods of treating a tumor

InactiveUS20210292415A1Increased proliferationIncrease PD- expressionPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsMelanomaAntiendomysial antibodies

This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and a CD-122-biased agonist. In some embodiments, the tumor is derived from a melanoma, a renal cell carcinoma (RCC), a non-small cell lung carcinoma (NSCLC), a urothelial cancer (UC), a breast cancer, or any combination thereof.

Owner:BRISTOL MYERS SQUIBB CO +1

8 results about "Internal medicine" patented technology

Popular searches